Journal article
Abstract P3-14-03: A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR MBC) and metastatic ovarian cancer (MOC)
Christina I Herold, Lorenzo Trippa, Tianyu Li, Khanh Do, Aditya Bardia, Leilani Anderson, Kamaneh Montazeri, Jessica Pittenger, Chelsea Andrews, Elizabeth A Mittendorf, Shom Goel, Eric P Winer, Geoffrey I Shapiro, Sara M Tolaney
Cancer Research | American Association for Cancer Research (AACR) | Published : 2020
Abstract
Abstract Background: Immune checkpoint inhibitors (ICI), such as those targeting the PD-1/PD-L1 axis, have shown modest activity as monotherapy in both HR+ MBC and MOC. Strategies to improve ICI for these diseases are under investigation. In mouse models, CDK4/6 inhibitors boost anti-tumor immunity in part by increasing the infiltration and activation of cytotoxic T lymphocytes, and by suppressing regulatory T lymphocyte function, providing rationale for combining CDK4/6 inhibition and ICI. Methods: We conducted an open-label phase 1b dose escalation study with the primary objectives of determining the safety, tolerability, maximum-tolerated dose (MTD) and recom..
View full abstract